AKT1 and renal cell carcinoma: PI3K signaling pathway is the master signaling controlling RCC development and progression.31 Inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mTOR, reach certain clinical benefits, however, major issues remain, such as limited efficacy or development of resistance to therapies.